Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ELDNNASDAQ:FATENASDAQ:INMBNASDAQ:MURA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeELDNEledon Pharmaceuticals$2.87-4.3%$3.05$2.30▼$5.54$171.86M-0.17276,172 shs195,097 shsFATEFate Therapeutics$1.28-8.9%$1.20$0.66▼$5.92$146.12M2.232.25 million shs2.43 million shsINMBINmune Bio$7.70-2.8%$7.53$4.32▼$10.50$176.98M1.55288,359 shs593,330 shsMURAMural Oncology$2.46-2.8%$2.44$0.95▼$4.74$42.48M3.361.31 million shs170,997 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceELDNEledon Pharmaceuticals0.00%-6.82%-0.69%-21.37%-3.04%FATEFate Therapeutics0.00%-20.31%+26.24%+35.42%-66.18%INMBINmune Bio0.00%+1.05%+5.62%-3.14%-12.00%MURAMural Oncology0.00%-3.91%-2.77%-36.92%-27.43%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationELDNEledon Pharmaceuticals2.8505 of 5 stars3.54.00.00.03.51.70.0FATEFate Therapeutics4.0819 of 5 stars3.13.00.04.72.61.70.6INMBINmune Bio1.8835 of 5 stars3.60.00.00.02.61.70.6MURAMural Oncology3.2439 of 5 stars3.35.00.00.02.01.71.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceELDNEledon Pharmaceuticals 3.00Buy$12.50335.54% UpsideFATEFate Therapeutics 2.22Hold$4.14224.93% UpsideINMBINmune Bio 3.17Buy$22.80196.10% UpsideMURAMural Oncology 2.60Moderate Buy$13.00428.46% UpsideCurrent Analyst Ratings BreakdownLatest MURA, FATE, INMB, and ELDN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/12/2025FATEFate TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold5/14/2025FATEFate TherapeuticsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$10.00 ➝ $2.005/14/2025FATEFate TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$5.00 ➝ $4.005/14/2025FATEFate TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold3/26/2025MURAMural OncologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$18.00 ➝ $6.003/25/2025MURAMural OncologyMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Equal Weight3/25/2025MURAMural OncologyRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Outperform$18.003/25/2025MURAMural OncologyJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold(Data available from 6/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookELDNEledon PharmaceuticalsN/AN/AN/AN/A$0.30 per shareN/AFATEFate Therapeutics$13.34M10.96N/AN/A$3.74 per share0.34INMBINmune Bio$50K3,539.54N/AN/A$2.07 per share3.72MURAMural OncologyN/AN/AN/AN/A$15.81 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateELDNEledon Pharmaceuticals-$116.54M-$2.10N/AN/AN/AN/A-189.99%-28.17%8/18/2025 (Estimated)FATEFate Therapeutics-$160.93M-$1.49N/AN/AN/A-1,325.43%-45.88%-33.95%8/12/2025 (Estimated)INMBINmune Bio-$30.01M-$1.93N/AN/AN/AN/A-117.48%-78.96%7/30/2025 (Estimated)MURAMural Oncology-$207.45M-$7.67N/AN/AN/AN/A-70.10%-61.30%8/12/2025 (Estimated)Latest MURA, FATE, INMB, and ELDN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025ELDNEledon Pharmaceuticals-$0.28-$0.08+$0.20-$0.08N/AN/A5/14/2025Q1 2025MURAMural Oncology-$2.12-$1.93+$0.19-$1.93N/AN/A5/13/2025Q1 2025FATEFate Therapeutics-$0.39-$0.32+$0.07-$0.32$1.18 million$1.63 million5/8/2025Q1 2025INMBINmune Bio-$0.43-$0.43N/A-$0.43N/A$0.05 million3/27/2025Q4 2024INMBINmune Bio-$0.54-$0.40+$0.14-$0.40N/AN/A3/20/2025Q4 2024ELDNEledon Pharmaceuticals-$0.32-$0.64-$0.32-$0.64N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthELDNEledon PharmaceuticalsN/AN/AN/AN/AN/AFATEFate TherapeuticsN/AN/AN/AN/AN/AINMBINmune BioN/AN/AN/AN/AN/AMURAMural OncologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioELDNEledon PharmaceuticalsN/A6.536.53FATEFate TherapeuticsN/A8.298.29INMBINmune BioN/A2.592.59MURAMural OncologyN/A7.387.38Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipELDNEledon Pharmaceuticals56.77%FATEFate Therapeutics97.54%INMBINmune Bio12.72%MURAMural Oncology80.21%Insider OwnershipCompanyInsider OwnershipELDNEledon Pharmaceuticals12.30%FATEFate Therapeutics5.51%INMBINmune Bio35.70%MURAMural Oncology2.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableELDNEledon Pharmaceuticals1059.88 million52.75 millionOptionableFATEFate Therapeutics550114.60 million108.20 millionOptionableINMBINmune Bio1022.98 million14.37 millionOptionableMURAMural Oncology11917.27 million17.01 millionOptionableMURA, FATE, INMB, and ELDN HeadlinesRecent News About These CompaniesBlackRock discloses 1.64% stake in Mural OncologyJune 13 at 11:27 PM | investing.comForm 8.3 - The Vanguard Group, Inc.: Mural Oncology plcJune 13 at 10:19 AM | markets.businessinsider.comBlackRock discloses 1.39% stake in Mural OncologyJune 12 at 6:59 PM | investing.comBlackRock Reveals 1.58% Holding in Mural OncologyJune 5, 2025 | msn.comCincinnati hospital honors late doctor with mural tributeMay 24, 2025 | local12.comGoldman Sachs adjusts positions in Mural OncologyMay 21, 2025 | investing.comMural Oncology Announces Number of Relevant Securities in IssueMay 19, 2025 | globenewswire.comBlackRock discloses stake in Mural Oncology plcMay 15, 2025 | investing.comLongtime Lawrence artist Louis Copt, known for Kansas landscape paintings, diesMay 10, 2025 | www2.ljworld.comBlackRock discloses stake in Mural OncologyMay 3, 2025 | investing.comGoldman Sachs discloses stake in Mural OncologyMay 3, 2025 | investing.comMural Oncology plc Opening Position Disclosure Under Irish Takeover RulesApril 30, 2025 | quiverquant.comFORM 8.1(a) & (b) - Mural Oncology plcApril 30, 2025 | globenewswire.com‘Final mark on his legacy’: Wood County artists dedicate work to muralist who died in JanuaryApril 30, 2025 | msn.comLuka Dončić donates entire cost of restoring vandalized Kobe Bryant mural in downtown Los AngelesApril 29, 2025 | msn.com“There is a life afterwards”: New downtown Dallas mural honors cancer survivorsApril 29, 2025 | keranews.orgParkwood Master Fund Ltd - Form 8.3 - Mural Oncology PlcApril 24, 2025 | uk.finance.yahoo.comForm 8.3 - Mural Oncology plcApril 22, 2025 | finance.yahoo.comBoston-area cancer research lab to cease drug trials, lay off 117April 22, 2025 | msn.comMass. biotech company cuts 90% of workforceApril 17, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeAnalysts Think These Stocks Could More Than Double in ValueBy Nathan Reiff | May 23, 2025View Analysts Think These Stocks Could More Than Double in ValueIntel’s Turnaround May Be the Best Bet No One’s WatchingBy Jeffrey Neal Johnson | May 30, 2025View Intel’s Turnaround May Be the Best Bet No One’s WatchingBullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBy Thomas Hughes | May 27, 2025View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsIn a Historic Shift, 2 Cybersecurity Stocks Plan to Buyback StockBy Leo Miller | June 9, 2025View In a Historic Shift, 2 Cybersecurity Stocks Plan to Buyback StockMURA, FATE, INMB, and ELDN Company DescriptionsEledon Pharmaceuticals NASDAQ:ELDN$2.87 -0.13 (-4.33%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$2.97 +0.10 (+3.48%) As of 06/13/2025 07:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.Fate Therapeutics NASDAQ:FATE$1.27 -0.13 (-8.93%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$1.28 +0.00 (+0.08%) As of 06/13/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.INmune Bio NASDAQ:INMB$7.70 -0.22 (-2.78%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$7.70 0.00 (0.00%) As of 06/13/2025 06:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.Mural Oncology NASDAQ:MURA$2.46 -0.07 (-2.77%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$2.47 +0.01 (+0.41%) As of 06/13/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops nemvaleukin to treat cutaneous melanoma and advanced solid tumors. The company is also developing engineered interleukin-18 and tumor-targeted interleukin-12 programs. Mural Oncology plc was incorporated in 2017 and is based in Dublin, Ireland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/09 - 06/13 Alphabet Enters a Bull Market: Is It Time to Buy? Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones RH Stock Rockets on Surprise Profit and Tariff Shift Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
